Bank of America’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bank of America’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-36,000	Closed	-$3.27M	–	8076
2023 Q1	$3.27M	Buy	+36,000	New	+$2.11M	﹤0.01%	3929
2022 Q4	–	Sell	-150,000	Closed	-$3.77M	–	8538
2022 Q3	$3.77M	Buy	+150,000	New	+$4.16M	﹤0.01%	3635

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of America's RETA Position: Q3 2023 in Review

Bank of America sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 87,846 shares — an estimated $8.96M sold.

Bank of America first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $20.2M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Bank of America reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Bank of America sold 87,846 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $8.96M.
Bank of America first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
Bank of America's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $20.2M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Bank of America's 13F filing for Q3 2023, filed 14 Nov 2023.